Cluster Hub

Bio

Biomanufacturing and regenerative medicine.

These 17 fields follow the strategic fields defined in Japan’s Growth Strategy (July 2026), not a categorisation invented by this site.

Priority products and technologies

2

Responsible: 経産省. The items below were selected in Japan's Growth Strategy (July 2026) for priority public and private investment in this field.

Figures are the government's own projections, not this site's estimates. Source: Japan's public-private investment roadmap (21 July 2026). See the original (Cabinet Secretariat) ↗ |The roadmap itself (PDF) ↗

Each digest condenses the government’s own selection rationale and direction (Growth Strategy Council, 10 Mar 2026 / Strategic Fields Subcommittee, 16 Apr 2026), written by this site. Item names follow the roadmap decided on 21 July 2026. Digests are provided in Japanese for now.

The mapping between items and associations is this site’s own arrangement, not a classification made by the government or the associations.

Associations in this field

Regenerative medicine
Chemicals (cross)
Healthcare DX (cross-field)
Life science co-creation

Events

Dates are when the event takes place, not when it was announced.

Announcements

Dates are when the association published the item.

Leading associations outside Japan

Outside Japan

Listed for comparison, and kept separate from Japanese announcements.

Recent announcements